Please use this identifier to cite or link to this item:
Title: Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice.
Austin Authors: Fifis, Theodora;Mottram, Patricia;Bogdanoska, Violeta;Hanley, Jennifer;Plebanski, Magdalena
Affiliation: Vaccine Development and Infectious Diseases Unit, Austin Research Institute, Austin Hospital, Studley Road, Heidelberg 3084, Victoria, Australia
Issue Date: 25-Nov-2004
Publication information: Vaccine; 23(2): 258-66
Abstract: Peptide based vaccines offer practical advantages, but unmodified peptides usually require an adjuvant or delivery vehicle to promote immunogenicity. When peptides containing ovalbumin (OVA) derived CD4 and CD8 T cell epitopes were conjugated to 0.05 microm nano-beads, they gave strong immune responses and inhibition of growth of tumour cells expressing the CD8 T cell epitope with MHC class I. These responses were inducible with both high (50 microg) and low (5 microg) peptide doses after a single immunisation. The helper CD4 T cell epitope was unnecessary for induction of CD8 T cell or tumour challenge responses. However, the CD4 T cell epitope contained a B cell epitope and triggered strong antibody responses. This simple approach offers a convenient experimental tool and a potentially useful clinical method for peptide immunisation.
Gov't Doc #: 15531045
DOI: 10.1016/j.vaccine.2004.05.022
Type: Journal Article
Subjects: Animals
Antigens, Neoplasm
Histocompatibility Antigens Class I.chemistry.pharmacology
Histocompatibility Antigens Class II.chemistry.pharmacology
Mice, Inbred C57BL
Peptides.chemical synthesis.chemistry.immunology.pharmacology
T-Lymphocytes.drug effects.immunology
Vaccines, Conjugate.administration & dosage.immunology
Vaccines, Synthetic.administration & dosage.immunology
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.